Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Evolution in ErbB2-Targeted Therapeutics for Breast Cancer
San Antonio Marriott Riverwalk
San Antonio, TX
December 13, 2008
Conference Overview
Growth factor and interrelated cellular pathways are important in breast cancer development and progression and have therefore been the focus of therapeutic strategies resulting in a significant impact on patient outcomes. In the past few years, an enormous amount of clinical information has been gathered regarding the use of ErbB-targeted agents in breast cancer, from metastatic disease to early-stage settings, and in numerous combinations and regimens. The Evolution in ErbB2-Targeted Therapeutics for Breast Cancer symposium will meet the need of physicians to synthesize recent data and approvals and integrate the new information into optimal clinical practice for their patients with breast cancer. Thesymposium will include educational cases and didactic lectures designed to update physicians and to facilitate the integration of new information on ErbB inhibitors into their clinical practice.
This educational program is directed toward medical and surgical oncologists, nurses, physician assistants, and other health care professionals interested in the treatment of breast cancer. Fellows in training with research and patient management interests in breast cancer are also invited to attend.At the conclusion of this symposium, you should be able to:
- Review the signal transduction and interrelated network events involved in breast cancer pathogenesis, including ErbB, hormone receptor, and angiogenic pathways, and the therapeutic modulators that target those pathways
- Evaluate recent clinical trial data on ErbB-targeted agents in metastatic breast cancer, including combination regimens designed to inhibit signaling at multiple points within a pathway or to inhibit cross-talk between pathways
- Assess the efficacy and safety of ErbB-targeted agents in the adjuvant or neoadjuvant setting and discuss the rationale for ongoing clinical trials
- Summarize current management standards and new strategies for the treatment of central nervous system metastases associated with ErbB2+ metastatic breast cancer
- Apply the above objectives in the context of specific clinical scenarios
Educational Grants
An educational grant for this activity was provided by:
- GlaxoSmithKline